



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_331_2

You asked:

I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated.

1. For the 4 months from January to April 2024, how many patients received the following intra-vitreal treatments for any eye condition:

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab - Ongavia

2. For the patients above, how many were new to intra-vitreal treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab - Ongavia

Our response:

In response to your recent enquiry above please find below a table populated with data that is available to Medicines Management for the period of January 24 to April 24, as requested.

Unfortunately, due to the way the data is recorded in our systems we are only able to provide number of injections used and we are not able to identify how many of the injections were administered to patients that are new to intra-vitreal treatment.

Medicine	Number of Injections
Aflibercept	1714
Bevacizumab	19
Brolucizumab	0
Dexamethasone	58
Faricimab	946
Ranibizumab - Lucentis	17
Ranibizumab - Ongavia	0

We can confirm that the Health Board does not centrally record the detailed information you require. To provide you with this data, would require a manual trawl through individual records. The Health Board estimates that the cost of locating, retrieving and extracting this data would significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.